Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nektar Seeking New Partner For Exubera As Pfizer Returns Rights

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer pays Nektar $135 million, resolving Exubera contract, and returns rights – providing Nektar finds a partner, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Does MannKind Finally Have What It Takes To Get Afrezza Inhaled Insulin Cleared By FDA?

Among other things, new FDA review will test whether the company has proven that data with an old device can be applied to the new inhaler the company plans to market. MannKind is not expecting an advisory committee meeting.

An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty

Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.

An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty

Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.

Related Content

Topics

UsernamePublicRestriction

Register

PS065350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel